IBB Stock Recent News

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.

The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, providing advantage in inflationary environment.

The long-awaited spot bitcoin ETFs are trading after a decade of waiting. So now the ETF and advisor community has some available brain capacity to look forward.

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

For investors seeking momentum, iShares Biotechnology ETF IBB is probably on the radar. The fund just hit a 52-week high and is up 25% from its 52-week low price of $11.83/share.

Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings.

Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.

Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.

This is a great time to examine the weekly charts of the Economic Modern Family. We like that timeframe for now with only a short number of trading days left.